{"id":"de-114-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Instillation site discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DE-114 inhibits Rho-associated coiled-coil containing protein kinase (ROCK), which plays a key role in regulating the cytoskeleton and cell contractility in the eye. By blocking ROCK signaling, the drug enhances drainage of aqueous humor through the uveoscleral pathway, thereby lowering intraocular pressure. This mechanism is distinct from prostaglandin analogs and other conventional glaucoma therapies.","oneSentence":"DE-114 is a selective rho kinase inhibitor that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:51.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma or ocular hypertension"}]},"trialDetails":[{"nctId":"NCT01363700","phase":"PHASE3","title":"Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"","conditions":"Allergic Conjunctivitis","enrollment":87},{"nctId":"NCT01363713","phase":"PHASE3","title":"A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"","conditions":"Allergic Conjunctivitis","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1907,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Epinastine ophthalmic solution"],"phase":"phase_3","status":"active","brandName":"DE-114 ophthalmic solution","genericName":"DE-114 ophthalmic solution","companyName":"Santen Pharmaceutical Co., Ltd.","companyId":"santen-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DE-114 ophthalmic solution is an oligosaccharide modality used to treat allergic conjunctivitis. It is being studied in a long-term open-label phase 3 clinical trial for its efficacy in patients with allergic conjunctivitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}